[go: up one dir, main page]

NI201200112A - Combinacion triple para reduccion de presion intraocular - Google Patents

Combinacion triple para reduccion de presion intraocular

Info

Publication number
NI201200112A
NI201200112A NI201200112A NI201200112A NI201200112A NI 201200112 A NI201200112 A NI 201200112A NI 201200112 A NI201200112 A NI 201200112A NI 201200112 A NI201200112 A NI 201200112A NI 201200112 A NI201200112 A NI 201200112A
Authority
NI
Nicaragua
Prior art keywords
intraocular pressure
pressure reduction
triple combination
iop
eye
Prior art date
Application number
NI201200112A
Other languages
English (en)
Inventor
P Pujara Chetan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43743470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201200112(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NI201200112A publication Critical patent/NI201200112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente instrumento se revelan las composiciones para disminuir la presión intraocular (PIO) de un ojo mediante la combinación de agentes que disminuyen la presión intra-ocular (PIO) bimatoprost, brimonidina y timolol. Además se revelan los métodos para reducir la PIO en el ojo de un sujeto.
NI201200112A 2009-12-22 2012-06-22 Combinacion triple para reduccion de presion intraocular NI201200112A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28893609P 2009-12-22 2009-12-22
US36174910P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
NI201200112A true NI201200112A (es) 2013-04-09

Family

ID=43743470

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200112A NI201200112A (es) 2009-12-22 2012-06-22 Combinacion triple para reduccion de presion intraocular

Country Status (15)

Country Link
US (1) US20130116254A1 (es)
CN (1) CN102695498A (es)
AR (1) AR079696A1 (es)
BR (1) BR112012017319A2 (es)
CL (1) CL2012001736A1 (es)
CO (1) CO6592061A2 (es)
CR (1) CR20120360A (es)
EC (1) ECSP12012033A (es)
GT (1) GT201200213A (es)
IN (1) IN2012DN06416A (es)
MX (1) MX2012007397A (es)
NI (1) NI201200112A (es)
PE (2) PE20121468A1 (es)
TW (1) TW201143773A (es)
WO (1) WO2011087790A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
EP3434257A1 (en) 2010-07-29 2019-01-30 Allergan, Inc. Preservative free brimonidine and timolol solutions
WO2013163219A1 (en) 2012-04-24 2013-10-31 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
AU2016233125A1 (en) * 2015-03-19 2017-09-14 Allergan, Inc. Fixed dose combination of bromonidine and timolol
WO2019246130A1 (en) * 2018-06-19 2019-12-26 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
US12064440B2 (en) * 2022-03-21 2024-08-20 Somerset Therapeutics, Llc Ophthalmic gel compositions of bimatoprost and timolol and associated methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution

Also Published As

Publication number Publication date
PE20121468A1 (es) 2012-10-28
CN102695498A (zh) 2012-09-26
US20130116254A1 (en) 2013-05-09
AR079696A1 (es) 2012-02-15
WO2011087790A1 (en) 2011-07-21
TW201143773A (en) 2011-12-16
CL2012001736A1 (es) 2012-10-12
BR112012017319A2 (pt) 2016-04-19
CO6592061A2 (es) 2013-01-02
GT201200213A (es) 2014-08-29
MX2012007397A (es) 2012-08-15
PE20160904A1 (es) 2016-09-16
CR20120360A (es) 2012-07-30
IN2012DN06416A (es) 2015-10-09
ECSP12012033A (es) 2012-10-30

Similar Documents

Publication Publication Date Title
AR120961A2 (es) Método y composición para tratar hipertensión ocular y glaucoma
NI201200112A (es) Combinacion triple para reduccion de presion intraocular
MX2012000889A (es) Compuesto biciclico y uso del mismo para propositos medicos.
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
MY171920A (en) Prevention and treatment of ocular conditions
CR8498A (es) Derivados de prostaglandinas
PH12013501579A1 (en) Androgen composition for treating an opthalmic condition
BRPI0512858A (pt) dispositivo de inserção de lente oftalmológica
EP3494959A3 (en) Sustained release latanoprost implant
ES2613698T3 (es) Combinación, kit y método de reducción de la presión intraocular
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.
ATE508711T1 (de) Vorgeformter intrastromaler hornhauteinsatz für hornhautanomalien oder -dystrophien
DOP2003000747A (es) Composiciones oftalmicas para el tratamiento de la hipertension ocular
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
CL2012002613A1 (es) Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular.
MX381356B (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
GT200600277A (es) Derivados de prostaglandina
MX2012003693A (es) Composiciones de olopatadine y usos de las mismas.
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
BR112012010795A2 (pt) Formulações oftálmicas contendo gama lactams substituídas e métodos para uso das mesmas
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.